BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors
NCT ID: NCT06152757
Last Updated: 2023-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
14 participants
INTERVENTIONAL
2023-10-09
2027-07-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Four dose levels were designed for this study: 1.0×10\^8cells, 3.0×10\^8cells, 1.0×10\^9cells, and 3.0×10\^9cells. The primary objective of this study was to evaluate the safety, tolerability and pharmacokinetic profile of BGT007H cell therapy in patients with recurrent/refractory digestive tract tumors, to determine the maximum tolerated dose or the best effective dose, and to initially evaluate the effectiveness of BGT007H cell products.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Evaluation of the safety and tolerability of BGT007H cell therapy in patients with recurrent/refractory gastrointestinal tumors
Secondary research objectives:
1. Evaluate the pharmacokinetic (PK) characteristics of BGT007H cells after reinfusion;
2. Evaluation of the initial effectiveness of BGT007H cell therapy in patients with recurrent/refractory gastrointestinal tumors
Exploratory Purpose
1. Exploring the correlation between the proliferation and survival of BGT007H cells in vivo and their therapeutic effects;
2. Exploring the correlation between target expression levels and efficacy
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BGT007H injection
Intravenous infusion
First dose
1.0×10\^8cells,Intravenous infusion，1 subject is planned to be enrolled
Second dose
3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
The third dose
1.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
The fourth dose
3.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
First dose
1.0×10\^8cells,Intravenous infusion，1 subject is planned to be enrolled
Second dose
3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
The third dose
1.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
The fourth dose
3.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2, age ≥18, male and female can;
* 3\. Expected survival ≥3 months;
* 4\. The Eastern Cancer Collaboration (ECOG) physical status score was 0-1;
* 5\. Biopsy specimen or pathological wax section test (within 3 years before accepting the signed informed consent) : positive target test;
* 6\. According to RECISTv1.1 solid tumor evaluation criteria, there is at least one measurable lesion;
* 7\. Patients with advanced gastrointestinal tumors (esophageal cancer, gastric cancer, pancreatic cancer or colorectal cancer, etc.) who have been diagnosed by histology/cytology as having failed the standard of second-line or above treatment or are not suitable for/refuse to accept the standard treatment or cannot tolerate the standard treatment; The definition of intolerance: according to CTCAE V5.0, the occurrence of ≥Ⅳ hematological toxicity or ≥Ⅲ non-hematological toxicity or ≥Ⅱ damage to the heart, liver, kidney and other important organs during treatment; Treatment failure is defined as disease progression (PD) during treatment or recurrence after the end of treatment (including postoperative recurrence);
* 8, can establish monopexy or venous blood collection venous access, and there are no other contraindications for blood cell separation;
* 9, with adequate organ and bone marrow function;
* 10\. During the study period and for 6 months after the end of dosing, fertile subjects (both male and female) must use effective medical contraception. For female subjects of reproductive age, a pregnancy test should be performed within 72 hours before the first dose, and the result is negative.
Exclusion Criteria
* 2, HIV positive, HBsAg positive simultaneously detected HBV DNA copy number positive (quantitative detection ≥1000cps/ml), HCV antibody positive and HCV RNA positive;
* 3, mental or mental illness can not cooperate with treatment and efficacy evaluation;
* 4\. Subjects with severe autoimmune diseases and long-term use of immunosuppressants;
* 5\. Active or uncontrollable infection requiring systemic treatment within 14 days prior to enrollment;
* 6\. Any unstable systemic disease (including but not limited to: Active infections (except local infections); Unstable angina pectoris Cerebral ischemia or cerebrovascular accident (within 6 months prior to screening) Myocardial infarction (within 6 months prior to screening) Congestive heart failure (New York Heart Association \[NYHA\] classification ≥Ⅲ; Severe arrhythmias requiring medical treatment; Have heart disease that requires treatment or uncontrolled hypertension after treatment (blood pressure \> 160mmHg/100mmHg);
* 7, combined with lung, brain, kidney and other important organ dysfunction;
* 8\. The subject has undergone major surgery or severe trauma within 4 weeks prior to receiving cell therapy, or is expected to undergo major surgery during the study period;
* 9\. Received any systemic chemotherapy, immunotherapy or small molecule targeted therapy within 1-2 weeks or 5 half-lives (whichever is shorter) before anapheresis;
* 10\. The subject currently has or has had other malignant tumors that cannot be cured within 3 years, except cervical cancer or basal cell carcinoma of the skin, and other malignant tumors with a disease-free survival of more than 5 years;
* 11, received chimeric antigen receptor modified T cells (including CAR-T, CTT-T) treatment within half a year;
* 12\. Combined graft-versus-host disease (GVHD)
* 13\. Subjects who were receiving systemic steroid therapy prior to screening and who were determined by the investigator to require long-term use of systemic steroid therapy during treatment (except for inhalation or topical use); And subjects treated with systemic steroids within 72 hours prior to cell transfusion (except for inhalation or topical use);
* 14\. Severe allergy or history of allergy;
* 15\. Subjects requiring anticoagulation therapy;
* 16, pregnant or breastfeeding women, or six months within the pregnancy plan (unisex;
* 17\. Researchers believe that there are other reasons for not being included in the treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of Zhengzhou University
OTHER
BioSyngen Pte Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yi Zhang
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Zhengzhou University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xinfeng Chen
Role: primary
Dan Wang
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR-BGT-003
Identifier Type: -
Identifier Source: org_study_id